To mention a few examples exploring this indication, synthetic cannabinoid WIN-55,212-2, a mixed CB1R/CB2R-receptor agonist, was tested on DRG neurons, and authors found significant results for neuropathic pain modulation through the inhibition of the TNF-α-induced expression/activity of NOS in the treated neurons (Tan and Cao, 2018) The same WIN-55,212-2 confers neuroprotection in a model of neonatal hypoxic-ischemic encephalopathy (Fernández-López et al., 2006) and protects the rat hippocampal neurons from excitotoxicity (Blanton et al., 2019). The gene discussed is CNR1; the disease is perinatal asphyxia.